Published in Blood Weekly, September 26th, 2002
New analysis from Frost & Sullivan, "U.S. Organ Transplant Pharmaceuticals Markets," reveals that this industry generated revenues totaling $1.20 billion in 2001. Total market revenues are expected to reach $3.26 billion in 2008.
The need for chronic and acute immunosuppressants is spurred by the need for improved organ transplant outcomes, which are currently plagued by rejection and adverse drug side effects.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.